Stem definition | Drug id | CAS RN |
---|---|---|
antihistaminics/cerebral (or peripheral) vasodilators | 1566 | 130018-77-8 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 71 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.18 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
May 25, 2007 | FDA | UCB INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urticaria | 75.27 | 12.52 | 131 | 13822 | 129430 | 50461741 |
Pruritus | 59.15 | 12.52 | 192 | 13761 | 283376 | 50307795 |
Asthma | 48.83 | 12.52 | 88 | 13865 | 89249 | 50501922 |
Drug-induced liver injury | 45.54 | 12.52 | 47 | 13906 | 28048 | 50563123 |
Angioedema | 45.47 | 12.52 | 54 | 13899 | 37622 | 50553549 |
Anaphylactic reaction | 42.80 | 12.52 | 63 | 13890 | 53992 | 50537179 |
Product use in unapproved indication | 40.65 | 12.52 | 95 | 13858 | 115724 | 50475447 |
Sinusitis | 38.69 | 12.52 | 119 | 13834 | 170439 | 50420732 |
Dermatitis contact | 36.16 | 12.52 | 25 | 13928 | 8621 | 50582550 |
Nail growth abnormal | 33.36 | 12.52 | 10 | 13943 | 471 | 50590700 |
Joint swelling | 33.30 | 12.52 | 13 | 13940 | 245273 | 50345898 |
Eye oedema | 30.12 | 12.52 | 12 | 13941 | 1331 | 50589840 |
Hepatitis chronic active | 29.09 | 12.52 | 6 | 13947 | 57 | 50591114 |
Product dose omission issue | 28.42 | 12.52 | 113 | 13840 | 183725 | 50407446 |
Contraindicated product administered | 27.80 | 12.52 | 4 | 13949 | 148954 | 50442217 |
Arthropathy | 27.77 | 12.52 | 5 | 13948 | 157901 | 50433270 |
Face oedema | 27.39 | 12.52 | 29 | 13924 | 17810 | 50573361 |
Abortion induced | 25.65 | 12.52 | 21 | 13932 | 9323 | 50581848 |
Hepatic encephalopathy | 25.08 | 12.52 | 21 | 13932 | 9615 | 50581556 |
Fixed eruption | 24.18 | 12.52 | 9 | 13944 | 830 | 50590341 |
Dermatitis atopic | 24.10 | 12.52 | 14 | 13939 | 3572 | 50587599 |
Lymphorrhoea | 23.92 | 12.52 | 5 | 13948 | 51 | 50591120 |
Completed suicide | 23.57 | 12.52 | 4 | 13949 | 131885 | 50459286 |
Psoriasis | 21.40 | 12.52 | 54 | 13899 | 68946 | 50522225 |
Bronchitis | 21.15 | 12.52 | 70 | 13883 | 104089 | 50487082 |
Cough | 21.13 | 12.52 | 126 | 13827 | 241138 | 50350033 |
Nasal congestion | 20.22 | 12.52 | 44 | 13909 | 51076 | 50540095 |
Glossodynia | 19.59 | 12.52 | 4 | 13949 | 115565 | 50475606 |
Drug intolerance | 19.50 | 12.52 | 19 | 13934 | 219085 | 50372086 |
Infusion site swelling | 19.43 | 12.52 | 16 | 13937 | 7160 | 50584011 |
Cholangiocarcinoma | 18.86 | 12.52 | 8 | 13945 | 1040 | 50590131 |
Rash morbilliform | 18.83 | 12.52 | 11 | 13942 | 2835 | 50588336 |
Cytogenetic analysis abnormal | 17.90 | 12.52 | 7 | 13946 | 739 | 50590432 |
Chest discomfort | 17.66 | 12.52 | 61 | 13892 | 92661 | 50498510 |
Swelling face | 17.19 | 12.52 | 42 | 13911 | 52553 | 50538618 |
Infusion site erythema | 16.73 | 12.52 | 16 | 13937 | 8711 | 50582460 |
Hereditary angioedema | 16.57 | 12.52 | 13 | 13940 | 5429 | 50585742 |
Abortion spontaneous | 16.57 | 12.52 | 36 | 13917 | 41736 | 50549435 |
Ear infection | 16.01 | 12.52 | 27 | 13926 | 25943 | 50565228 |
Foreign body in throat | 15.49 | 12.52 | 4 | 13949 | 108 | 50591063 |
Infusion site pain | 15.39 | 12.52 | 18 | 13935 | 12328 | 50578843 |
Alopecia totalis | 15.25 | 12.52 | 5 | 13948 | 317 | 50590854 |
Death | 15.17 | 12.52 | 43 | 13910 | 325336 | 50265835 |
Analgesic drug level increased | 15.03 | 12.52 | 8 | 13945 | 1723 | 50589448 |
Upper respiratory tract infection | 14.93 | 12.52 | 46 | 13907 | 65852 | 50525319 |
Arrhythmia | 14.82 | 12.52 | 30 | 13923 | 33102 | 50558069 |
Dry skin | 14.66 | 12.52 | 35 | 13918 | 43156 | 50548015 |
Eczema | 14.53 | 12.52 | 24 | 13929 | 22678 | 50568493 |
Jaundice | 14.37 | 12.52 | 26 | 13927 | 26403 | 50564768 |
Serotonin syndrome | 14.32 | 12.52 | 25 | 13928 | 24688 | 50566483 |
Cross sensitivity reaction | 14.07 | 12.52 | 8 | 13945 | 1961 | 50589210 |
Headache | 13.88 | 12.52 | 206 | 13747 | 506329 | 50084842 |
Alopecia areata | 13.83 | 12.52 | 7 | 13946 | 1361 | 50589810 |
Exposure during pregnancy | 13.82 | 12.52 | 68 | 13885 | 120947 | 50470224 |
Wound | 13.70 | 12.52 | 6 | 13947 | 105788 | 50485383 |
Vascular injury | 13.59 | 12.52 | 6 | 13947 | 859 | 50590312 |
Laryngopharyngitis | 13.54 | 12.52 | 3 | 13950 | 41 | 50591130 |
Coronavirus infection | 13.51 | 12.52 | 9 | 13944 | 2920 | 50588251 |
Treatment failure | 13.35 | 12.52 | 11 | 13942 | 137626 | 50453545 |
Hepatitis cholestatic | 13.24 | 12.52 | 12 | 13941 | 6105 | 50585066 |
Toxicity to various agents | 13.21 | 12.52 | 24 | 13929 | 212475 | 50378696 |
COVID-19 | 12.91 | 12.52 | 35 | 13918 | 46627 | 50544544 |
Abortion missed | 12.84 | 12.52 | 7 | 13946 | 1581 | 50589590 |
Bronchospasm | 12.75 | 12.52 | 18 | 13935 | 14836 | 50576335 |
Systemic lupus erythematosus | 12.73 | 12.52 | 12 | 13941 | 140610 | 50450561 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal malformation | 66.13 | 14.93 | 13 | 6338 | 125 | 29568051 |
Trisomy 18 | 61.58 | 14.93 | 13 | 6338 | 183 | 29567993 |
Drug-induced liver injury | 48.68 | 14.93 | 39 | 6312 | 21616 | 29546560 |
Sinusitis | 40.28 | 14.93 | 43 | 6308 | 34307 | 29533869 |
Alopecia areata | 39.15 | 14.93 | 9 | 6342 | 191 | 29567985 |
Fixed eruption | 38.22 | 14.93 | 13 | 6338 | 1189 | 29566987 |
Product use in unapproved indication | 32.48 | 14.93 | 63 | 6288 | 86812 | 29481364 |
Febrile convulsion | 30.21 | 14.93 | 9 | 6342 | 536 | 29567640 |
Neonatal hyponatraemia | 29.23 | 14.93 | 6 | 6345 | 73 | 29568103 |
Pruritus | 29.16 | 14.93 | 72 | 6279 | 116777 | 29451399 |
Erythema | 28.46 | 14.93 | 55 | 6296 | 75551 | 29492625 |
Anaphylactic reaction | 27.97 | 14.93 | 32 | 6319 | 27541 | 29540635 |
Hypothermia | 25.93 | 14.93 | 19 | 6332 | 9220 | 29558956 |
Asthma | 25.78 | 14.93 | 34 | 6317 | 33815 | 29534361 |
Dermatitis atopic | 24.02 | 14.93 | 11 | 6340 | 2208 | 29565968 |
Pemphigoid | 22.21 | 14.93 | 16 | 6335 | 7565 | 29560611 |
Urticaria | 20.84 | 14.93 | 40 | 6311 | 54620 | 29513556 |
Congenital inguinal hernia | 19.85 | 14.93 | 5 | 6346 | 158 | 29568018 |
Periportal oedema | 18.97 | 14.93 | 4 | 6347 | 56 | 29568120 |
Hypogammaglobulinaemia | 18.53 | 14.93 | 13 | 6338 | 5894 | 29562282 |
Neonatal seizure | 18.44 | 14.93 | 6 | 6345 | 478 | 29567698 |
Rash maculo-papular | 17.88 | 14.93 | 24 | 6327 | 24265 | 29543911 |
Erythema multiforme | 17.54 | 14.93 | 14 | 6337 | 7703 | 29560473 |
Renal aplasia | 16.57 | 14.93 | 6 | 6345 | 660 | 29567516 |
Eyelid oedema | 16.43 | 14.93 | 11 | 6340 | 4625 | 29563551 |
Facial discomfort | 16.11 | 14.93 | 3 | 6348 | 21 | 29568155 |
Face oedema | 15.96 | 14.93 | 15 | 6336 | 10268 | 29557908 |
Suspected suicide attempt | 15.95 | 14.93 | 4 | 6347 | 124 | 29568052 |
Trigeminal nerve disorder | 15.34 | 14.93 | 3 | 6348 | 28 | 29568148 |
Carbuncle | 15.24 | 14.93 | 3 | 6348 | 29 | 29568147 |
Idiosyncratic drug reaction | 15.10 | 14.93 | 5 | 6346 | 421 | 29567755 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug-induced liver injury | 87.69 | 12.56 | 83 | 16623 | 47560 | 64434466 |
Pruritus | 86.65 | 12.56 | 225 | 16481 | 312175 | 64169851 |
Urticaria | 81.77 | 12.56 | 141 | 16565 | 147176 | 64334850 |
Fixed eruption | 59.36 | 12.56 | 22 | 16684 | 2137 | 64479889 |
Febrile convulsion | 57.83 | 12.56 | 17 | 16689 | 798 | 64481228 |
Product use in unapproved indication | 55.99 | 12.56 | 134 | 16572 | 176484 | 64305542 |
Anaphylactic reaction | 55.21 | 12.56 | 78 | 16628 | 68586 | 64413440 |
Angioedema | 52.34 | 12.56 | 72 | 16634 | 61749 | 64420277 |
Asthma | 47.45 | 12.56 | 87 | 16619 | 95138 | 64386888 |
Dermatitis contact | 46.46 | 12.56 | 29 | 16677 | 8971 | 64473055 |
Alopecia areata | 43.60 | 12.56 | 16 | 16690 | 1512 | 64480514 |
Face oedema | 41.51 | 12.56 | 41 | 16665 | 24720 | 64457306 |
Completed suicide | 36.39 | 12.56 | 7 | 16699 | 224407 | 64257619 |
Dermatitis atopic | 32.11 | 12.56 | 17 | 16689 | 3859 | 64478167 |
Eye oedema | 30.93 | 12.56 | 13 | 16693 | 1760 | 64480266 |
Nail growth abnormal | 30.20 | 12.56 | 9 | 16697 | 443 | 64481583 |
Toxicity to various agents | 27.74 | 12.56 | 32 | 16674 | 363481 | 64118545 |
Erythema | 26.32 | 12.56 | 107 | 16599 | 186963 | 64295063 |
Cough | 26.01 | 12.56 | 150 | 16556 | 301998 | 64180028 |
Joint swelling | 25.41 | 12.56 | 12 | 16694 | 215370 | 64266656 |
Hepatic encephalopathy | 24.92 | 12.56 | 29 | 16677 | 21037 | 64460989 |
Swelling face | 23.31 | 12.56 | 49 | 16657 | 59117 | 64422909 |
Hepatitis chronic active | 22.97 | 12.56 | 6 | 16700 | 181 | 64481845 |
Erythema multiforme | 22.68 | 12.56 | 24 | 16682 | 15677 | 64466349 |
Sinusitis | 22.57 | 12.56 | 86 | 16620 | 145842 | 64336184 |
Drug eruption | 20.54 | 12.56 | 35 | 16671 | 36101 | 64445925 |
Rash morbilliform | 20.27 | 12.56 | 14 | 16692 | 5127 | 64476899 |
Lymphorrhoea | 20.11 | 12.56 | 5 | 16701 | 123 | 64481903 |
Pyrexia | 19.22 | 12.56 | 225 | 16481 | 558419 | 63923607 |
Psoriasis | 19.12 | 12.56 | 51 | 16655 | 71652 | 64410374 |
Rash maculo-papular | 18.59 | 12.56 | 39 | 16667 | 46987 | 64435039 |
Prescribed overdose | 17.68 | 12.56 | 24 | 16682 | 20307 | 64461719 |
Activated partial thromboplastin time prolonged | 17.46 | 12.56 | 19 | 16687 | 12812 | 64469214 |
Rash | 16.79 | 12.56 | 187 | 16519 | 458362 | 64023664 |
Bronchospasm | 16.49 | 12.56 | 24 | 16682 | 21658 | 64460368 |
Eyelid oedema | 16.39 | 12.56 | 18 | 16688 | 12261 | 64469765 |
Product dose omission issue | 16.28 | 12.56 | 96 | 16610 | 194651 | 64287375 |
Suspected suicide attempt | 16.26 | 12.56 | 5 | 16701 | 274 | 64481752 |
Obsessive thoughts | 16.22 | 12.56 | 7 | 16699 | 1010 | 64481016 |
Drug abuse | 16.19 | 12.56 | 7 | 16699 | 132367 | 64349659 |
Drug intolerance | 16.06 | 12.56 | 15 | 16691 | 187977 | 64294049 |
Periportal oedema | 15.88 | 12.56 | 4 | 16702 | 104 | 64481922 |
Eczema | 15.87 | 12.56 | 28 | 16678 | 29692 | 64452334 |
Alopecia totalis | 15.71 | 12.56 | 5 | 16701 | 307 | 64481719 |
Cerebrovascular accident | 15.71 | 12.56 | 8 | 16698 | 137575 | 64344451 |
Pemphigoid | 15.56 | 12.56 | 18 | 16688 | 12968 | 64469058 |
Interstitial lung disease | 15.43 | 12.56 | 58 | 16648 | 97674 | 64384352 |
Abortion missed | 15.27 | 12.56 | 7 | 16699 | 1165 | 64480861 |
Hypothermia | 15.13 | 12.56 | 22 | 16684 | 19834 | 64462192 |
Hyperventilation | 14.69 | 12.56 | 13 | 16693 | 6827 | 64475199 |
Altered state of consciousness | 14.48 | 12.56 | 31 | 16675 | 37871 | 64444155 |
Eosinophilia | 14.38 | 12.56 | 31 | 16675 | 38045 | 64443981 |
Eosinophilic granulomatosis with polyangiitis | 14.16 | 12.56 | 9 | 16697 | 2873 | 64479153 |
Intraductal proliferative breast lesion | 13.87 | 12.56 | 8 | 16698 | 2143 | 64479883 |
Arthropathy | 13.86 | 12.56 | 7 | 16699 | 120960 | 64361066 |
Analgesic drug level increased | 13.47 | 12.56 | 8 | 16698 | 2262 | 64479764 |
Foreign body in throat | 13.30 | 12.56 | 4 | 16702 | 203 | 64481823 |
Acute hepatic failure | 13.17 | 12.56 | 24 | 16682 | 26088 | 64455938 |
Facial discomfort | 13.12 | 12.56 | 3 | 16703 | 51 | 64481975 |
Stevens-Johnson syndrome | 13.07 | 12.56 | 28 | 16678 | 34221 | 64447805 |
Laryngopharyngitis | 12.96 | 12.56 | 3 | 16703 | 54 | 64481972 |
Death | 12.83 | 12.56 | 73 | 16633 | 482632 | 63999394 |
Acoustic neuroma | 12.77 | 12.56 | 4 | 16702 | 233 | 64481793 |
Nasal congestion | 12.58 | 12.56 | 39 | 16667 | 59619 | 64422407 |
None
Source | Code | Description |
---|---|---|
ATC | R06AE09 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Piperazine derivatives |
FDA MoA | N0000000190 | Histamine H1 Receptor Antagonists |
FDA EPC | N0000175587 | Histamine-1 Receptor Antagonist |
MeSH PA | D018494 | Histamine Agents |
MeSH PA | D006633 | Histamine Antagonists |
MeSH PA | D006634 | Histamine H1 Antagonists |
MeSH PA | D039563 | Histamine H1 Antagonists, Non-Sedating |
MeSH PA | D018377 | Neurotransmitter Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Allergic rhinitis | indication | 61582004 | |
Chronic idiopathic urticaria | indication | 302162004 | |
Seasonal allergic rhinitis | indication | 367498001 | |
Atopic dermatitis | off-label use | 24079001 | DOID:3310 |
Urticaria | off-label use | 126485001 | |
Chronic renal failure syndrome | contraindication | 90688005 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Drowsy | contraindication | 271782001 | |
Hemodialysis with High-Flux Membrane | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.03 | acidic |
pKa2 | 8.21 | Basic |
pKa3 | 3.72 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 7.95 | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
D07402 | KEGG_DRUG |
823178-28-5 | SECONDARY_CAS_RN |
130018-87-0 | SECONDARY_CAS_RN |
4026739 | VANDF |
4026740 | VANDF |
C1174893 | UMLSCUI |
CHEBI:94559 | CHEBI |
CHEMBL1201191 | ChEMBL_ID |
CHEMBL1201190 | ChEMBL_ID |
DB06282 | DRUGBANK_ID |
C472067 | MESH_SUPPLEMENTAL_RECORD_UI |
1549000 | PUBCHEM_CID |
7700 | INN_ID |
6U5EA9RT2O | UNII |
356887 | RXNORM |
178562 | MMSL |
18517 | MMSL |
83855 | MMSL |
d05851 | MMSL |
009491 | NDDF |
009492 | NDDF |
391595003 | SNOMEDCT_US |
421889003 | SNOMEDCT_US |
425461004 | SNOMEDCT_US |
LCR | PDB_CHEM_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Levocetirizine Dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7701 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
good sense levocetirizine | HUMAN OTC DRUG LABEL | 1 | 0113-0241 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
levocetirizine | HUMAN OTC DRUG LABEL | 1 | 0363-2241 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
allergy relief | HUMAN OTC DRUG LABEL | 1 | 0363-3901 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 0363-5528 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 0363-5529 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
Levocetirizine Dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1917 | SOLUTION | 0.50 mg | ORAL | ANDA | 25 sections |
Levocetirizine Dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1917 | SOLUTION | 0.50 mg | ORAL | ANDA | 25 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 0536-1144 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
Levocetirizine Dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-639 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 11673-847 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
allergy relief | HUMAN OTC DRUG LABEL | 1 | 11822-0241 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 11822-5252 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
Allergy Relief | HUMAN OTC DRUG LABEL | 1 | 21130-732 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 30142-717 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
Levocetirizine Dihydrochloride | Human Prescription Drug Label | 1 | 31722-551 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
levocetirizine dihydrochloride | Human Prescription Drug Label | 1 | 31722-659 | SOLUTION | 2.50 mg | ORAL | ANDA | 25 sections |
Levocetirizine Dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-947 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
LEVOCETIRIZINE DIHYDROCHLORIDE | Human Prescription Drug Label | 1 | 33342-200 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
Topcare All Day Allergy | HUMAN OTC DRUG LABEL | 1 | 36800-241 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
Topcare All Day Allergy | HUMAN OTC DRUG LABEL | 1 | 36800-241 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 37808-126 | TABLET, COATED | 5 mg | ORAL | ANDA | 15 sections |
levocetirizine dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 41163-938 | TABLET, COATED | 5 mg | ORAL | ANDA | 14 sections |
Xyzal Allergy 24HR | HUMAN OTC DRUG LABEL | 1 | 41167-3510 | TABLET | 5 mg | ORAL | NDA | 15 sections |
Childrens Xyzal Allergy | HUMAN OTC DRUG LABEL | 1 | 41167-3530 | SOLUTION | 0.50 mg | ORAL | NDA | 14 sections |
Allergy Relief | HUMAN OTC DRUG LABEL | 1 | 41250-488 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 15 sections |
Levocetirizine Dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-386 | TABLET | 5 mg | ORAL | ANDA | 18 sections |
levocetirizine dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-712 | TABLET | 5 mg | ORAL | ANDA | 26 sections |
Levocetirizine Dihydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-122 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
Levocetirizine Dihydrochloride | HUMAN OTC DRUG LABEL | 1 | 42571-312 | TABLET | 5 mg | ORAL | ANDA | 16 sections |